| 0.695 -0.015 (-2.11%) | 04-16 12:43 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.97 |
1-year : | 1.12 |
| Resists | First : | 0.83 |
Second : | 0.95 |
| Pivot price | 0.82 |
|||
| Supports | First : | 0.63 |
Second : | 0.52 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.83 |
| MA(100) : | 0.79 |
MA(250) : | 1.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 20.9 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 4.67 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CARA ] has closed above bottom band by 2.6%. Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.79 | 0.79 - 0.79 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Tue, 16 Apr 2024
Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78% - Yahoo Lifestyle UK
Mon, 15 Apr 2024
Cara Therapeutics, Inc. Expected to Post FY2028 Earnings of ($0.21) Per Share (NASDAQ:CARA) - Defense World
Thu, 11 Apr 2024
Cara Therapeutics' (CARA) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Tue, 09 Apr 2024
Cara Therapeutics executive sells over $2,000 in stock By Investing.com - Investing.com
Tue, 09 Apr 2024
Cara Therapeutics CMO sells shares worth over $2,000 By Investing.com - Investing.com
Tue, 02 Apr 2024
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 3.935e+007 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 2,390 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2124e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 85.4 % |
| Return on Equity (ttm) | -49.3 % |
| Qtrly Rev. Growth | 2.097e+007 % |
| Gross Profit (p.s.) | -11.29 |
| Sales Per Share | -156.86 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.45 |
| Dividend | 0 |
| Forward Dividend | 2.58e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|